Article Text

PDF
Natriuretic peptides as a prognostic marker and therapeutic target in heart failure
  1. G A Wright,
  2. A D Struthers
  1. Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, Dundee, UK
  1. Correspondence to:
    Dr Gary A Wright
    Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK; gary.gawright{at}gmail.com

Abstract

Natriuretic peptides may have an increasing role in assisting clinicians to target treatment in patients with chronic heart failure

  • ACE, angiotensin converting enzyme
  • ANP, atrial natriuretic peptide
  • BNP, B-type natriuretic peptide
  • CHF, chronic heart failure
  • ICD, implantable cardioverter-defibrillator
  • LVEF, left ventricular ejection fraction
  • MADIT, multicenter automatic defibrillator implantation trial
  • NYHA, New York Heart Association
  • Val-HeFT, valsartan heart failure trial
  • B-type natriuretic peptide
  • BNP
  • prognosis
  • heart failure
  • therapy

Statistics from Altmetric.com

Footnotes

  • Both authors declare that we have no competing interests.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.